Shanghai Juncell Therapeutics

This early-phase study tests a new treatment called GC203 TIL for people with pancreatic cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are collected from their tumor, genetically modified to fight cancer better, and th…

This early-phase study tests a personalized cell therapy (GC101 TIL) for people with advanced gastrointestinal tumors that have not responded to standard treatments. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after a short che…

This study tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. The treatment uses a patient's own immune cells, grown in a lab, to fight the cancer. About 98 participants will be randomly assigned to receive either t…

This early-phase study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. Doctors take immune cells from a patient's own tumor, grow them in a lab, and infuse them back into the patient. The goal is to see if this approach i…

This study tests a new treatment for people with advanced liver or pancreatic cancers that have not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in large numbers in a lab, and then given back to the patient. The goal i…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's tumor, grow them in a lab, and put them back into the body after a short chemotherapy. The goal is to shrink tum…

This early-stage study tests a treatment using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight advanced solid tumors. About 30 adults who have not responded to standard treatments will receive these cells along with chemotherapy. The main goal…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the body to fight the cancer. The study w…

This study tests a treatment made from a patient's own immune cells (called TILs) to fight advanced melanoma. Doctors take a sample of the tumor, grow the immune cells in a lab, and then put them back into the patient. The goal is to shrink tumors and control the cancer, but pati…

This early-stage study tests a new treatment called GC201 TIL for people with advanced gynecologic cancers that have not responded to standard therapies. Doctors take immune cells from the patient's tumor, modify them to better fight cancer, and then return them to the body. The …

This early-stage study tests a treatment called TIL therapy for people with brain glioma who have not responded to standard treatments. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the body to attack the cancer. The goal is to…